| Biomarker ID | 962 |
| PMID | 22821756 |
| Year | 2012 |
| Biomarker | Prostate Cancer Antigen 3 (PCA3) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Urine |
| Subjects | Humans |
| Regulation | Upregulated in PCa [No PCa: 32 (13.5–68) Vs PCa 50 (34–83)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | PCa Vs No-PCa |
| Type of Biomarker | Diagnostic |
| Cohort | 160 patients were included in the study, ouut of which 113 did not have prostate cancer and 47 had prostate cancer. |
| Senstivity | 0.83 (95% CI: 0.72–0.94) |
| Specificity | 0.51 (95% CI:0.42–0.61) |
| AUC | 0.71 (95% CI: 0.61–0.80) |
| Accuracy | NA |
| Level Of Significance | p=0.001 |
| Method Used | NA |
| Clinical | No |
| Remarks | The PCA3 score was calculated as mRNA PCA3/mRNA PSA x 1000 |
| Clinical Trial Number | NA |
| Degree Of Validity | not validated on independent patient dataset |
| Technical Name | NA |